18F-DOPA PET引导下再程放疗治疗复发高级别胶质瘤的II期试验初步结果
这项II期试验纳入20例既往接受过放疗的复发或进展性高级别胶质瘤成人患者,采用18F-DOPA PET与MRI引导再程放疗(35 Gy/10次),主要终点3个月无进展生存率为85%(95% CI 63.2-95.8%),达到预设的PFS3≥40%目标;4例(20%)发生3级毒性,无4-5级毒性。
要点
- 18F-DOPA PET使MRI定义靶区中位扩大43%(范围0-436%)。
- 3个月无进展生存率85%(95% CI 63.2-95.8%),达到主要终点。
- 再程放疗后失败位于MRI与PET共同肿瘤体积内者占75%。
核心结论
- 18F-DOPA PET引导下再程放疗用于进展性高级别胶质瘤看来安全,并值得进一步研究。
研究设计与样本
- II期试验,纳入既往接受过放疗的复发或进展性高级别胶质瘤成人患者,20例按方案完成治疗。
- 主要终点为3个月无进展生存率较历史对照(单纯全身治疗20%)提高20%,即PFS3≥40%。
- 再程放疗剂量为35 Gy分10次,靶区为MRI T1增强定义的肿瘤加18F-DOPA PET定义的肿瘤。
主要发现
- 诊断以胶质母细胞瘤IDH野生型最常见(60%)。
- 利用18F-DOPA PET使MRI定义体积中位扩大43%(范围0-436%)。
- 3个月无进展生存率为85%(95% CI 63.2-95.8%),达到主要终点。
- 中位随访9.7个月时,17例(85%)进展,15例(75%)死亡;再程放疗后中位总生存期为8.8个月。
- 再程放疗后失败位于MRI与PET肿瘤体积内者占75%,仅MRI内占13%,仅PET内占0%,两者之外占13%;4例(20%)发生3级毒性,包括中枢神经系统坏死(n=2,均无症状,因影像学发现开始贝伐珠单抗)、癫痫发作(n=1)、乏力(n=1)和恶心(n=1),未观察到4-5级毒性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: In-field high-grade glioma (HGG) recurrence is a common challenge with limited treatment options, including re-irradiation. The radiotracer 3,4-dihydroxy-6-[18F]-fluoro-L-phenylalanine (18F-DOPA) crosses the blood brain barrier and demonstrates high uptake in tumor, but low uptake in normal tissue. This study investigated whether 18F-DOPA positron emission tomography (PET) and MRI guided re-irradiation for recurrent HGG may improve progression free survival (PFS). METHODS: Adults with recurrent or progressive HGG previously treated with radiation were eligible. The primary endpoint was a 20% improvement from the historical control PFS at 3 months (PFS3) of 20% with systemic therapy alone. Re-RT dose was 35 Gy in 10 fractions. The target volume was MRI T1 contrast-enhancement defined tumor plus 18F-DOPA PET defined tumor. RESULTS: Twenty patients completed treatment per protocol. Diagnosis was most commonly glioblastoma, IDH-wildtype (60%). MRI-defined volumes were expanded by a median 43% (0-436%) by utilizing 18F-DOPA PET. PFS3 was 85% (95% CI 63.2-95.8%), meeting the primary endpoint of PFS3 ≥ 40%. With 9.7 months median follow-up, 17 (85%) had progressed and 15 (75%) had died. Median OS from re-RT was 8.8 months. Failure following re-RT was within both the MRI and PET tumor volumes in 75%, MRI only in 13%, PET only in 0%, and neither in 13%. Four (20%) patients experienced grade 3 toxicity, including CNS necrosis (n = 2, both asymptomatic with bevacizumab initiation for radiographic findings), seizures (n = 1), fatigue (n = 1), and nausea (n = 1). No grade 4-5 toxicities were observed. CONCLUSION: 18F-DOPA PET-guided re-irradiation for progressive high-grade glioma appears safe and promising for further investigation.
引用
- Breen WG, Youland RS, Giri S, et al. Initial results of a phase II trial of 18F-DOPA PET-guided re-irradiation for recurrent high-grade glioma. J Neurooncol. 2022. PMID: 35583721. doi:10.1007/s11060-022-04011-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。